cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biocryst Pharmaceuticals Inc
45 own
50 watching
Current Price
$10.55
$0.21
(2.03%)
logo-bcrx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,966.64M
52-Week High
52-Week High
19.99
52-Week Low
52-Week Low
7.61
Average Volume
Average Volume
2.31M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,966.64M
icon52-Week High19.99
icon52-Week Low7.61
iconAverage Volume2.31M
iconDividend Yield--
iconP/E Ratio--
What does the Biocryst Pharmaceuticals Inc do?
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More
How much money does Biocryst Pharmaceuticals Inc make?
News & Events about Biocryst Pharmaceuticals Inc.
Globe Newswire
9days ago
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO (berotralstat) in Central and Eastern Europe (CEE). We continue to build ...
Globe Newswire
23days ago
ORLADEYO preliminary 2022 full year net revenue of $251.6 million (+105 percent y-o-y) ORLADEYO net revenue expected to be no less than $320 million in 2023 Company expects ORLADEYO peak sales of $1 billion RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc...
Globe Newswire
23days ago
Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2 RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that initial data from ongoing phase 1 ...
Globe Newswire
27days ago
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCrysts board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 178,100 shares, and restricted stock...
Globe Newswire
2 months ago
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO (berotralstat) to prevent attacks of hereditary angioedema (HAE) in ...
Frequently Asked Questions
Frequently Asked Questions
What is Biocryst Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Biocryst Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Biocryst Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Biocryst Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biocryst Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Biocryst Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Biocryst Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biocryst Pharmaceuticals Inc?
plus_minus_icon
What percentage is Biocryst Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biocryst Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.55
$0.21
(2.03%)
logo-bcrx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00